157 related articles for article (PubMed ID: 32047540)
1. Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma.
Feng JF; Wang L; Yang X; Chen S
J Cancer; 2020; 11(6):1334-1340. PubMed ID: 32047540
[No Abstract] [Full Text] [Related]
2. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
3. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.
Shi Y; Shen G; Zeng Y; Ju M; Chen X; He C; Liang L; Ge X; Sun X; Di X
Int Immunopharmacol; 2023 Oct; 123():110773. PubMed ID: 37562292
[TBL] [Abstract][Full Text] [Related]
4. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.
Li Y; Pan Y; Lin X; Hou J; Hu Z; Xu L; Zhou Z; Zhang Y; Chen M; Hu D
Front Pharmacol; 2021; 12():819985. PubMed ID: 35237150
[No Abstract] [Full Text] [Related]
6. Prognostic value of lactate dehydrogenase to albumin ratio (LAR) in patients with resectable esophageal squamous cell carcinoma.
Feng JF; Wang L; Yang X; Jiang YH
Cancer Manag Res; 2019; 11():7243-7251. PubMed ID: 31447584
[TBL] [Abstract][Full Text] [Related]
7. A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio.
Zhao Q; Chen S; Feng JF
Oncotarget; 2017 Nov; 8(61):103535-103542. PubMed ID: 29262582
[TBL] [Abstract][Full Text] [Related]
8. Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: A propensity score matching retrospective cohort study.
Li SJ; Zhao L; Wang HY; Zhou HN; Ju J; Du H; Che GW
Int J Surg; 2020 Dec; 84():25-40. PubMed ID: 33086147
[TBL] [Abstract][Full Text] [Related]
9. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
10. Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study.
Shangguan J; Huang X; Liu X; Zhang Z; Zhang X; Yu J; Chen D
Front Oncol; 2023; 13():1195499. PubMed ID: 37205200
[TBL] [Abstract][Full Text] [Related]
11. Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis.
Tian S; Cao Y; Duan Y; Liu Q; Peng P
Front Oncol; 2021; 11():737283. PubMed ID: 34917499
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Derived NLR Score is a Novel Prognostic Marker for Esophageal Squamous Cell Carcinoma.
Abe T; Oshikiri T; Goto H; Kato T; Horikawa M; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Kakeji Y
Ann Surg Oncol; 2022 Apr; 29(4):2663-2671. PubMed ID: 34807322
[TBL] [Abstract][Full Text] [Related]
13. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801320
[TBL] [Abstract][Full Text] [Related]
14. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
15. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
16. The preoperative hemoglobin, albumin, lymphocyte and platelet (HALP) score is a useful predictor in patients with resectable esophageal squamous cell carcinoma.
Feng JF; Wang L; Yang X
Bosn J Basic Med Sci; 2021 Dec; 21(6):773-781. PubMed ID: 33974528
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of Osaka prognostic score based on nutritional and inflammatory status in patients with esophageal squamous cell carcinoma.
Feng J; Wang L; Wang L; Yang X; Lou G
BMC Cancer; 2022 Mar; 22(1):284. PubMed ID: 35300627
[TBL] [Abstract][Full Text] [Related]
18. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
Hatanaka T; Naganuma A; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Kakizaki S; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Cancer Med; 2023 Feb; 12(4):4259-4269. PubMed ID: 36156452
[TBL] [Abstract][Full Text] [Related]
19. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
Tanabe K; Kobayashi S; Maezawa Y; Ishihara K; Inoue N; Izumi K; Fujiwara M; Toide M; Yamamoto T; Uehara S; Araki S; Inoue M; Takazawa R; Numao N; Ohtsuka Y; Tanaka H; Yoshida S; Fujii Y
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38833113
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma.
Basoglu T; Babacan NA; Ozturk FE; Arikan R; Demircan NC; Telli TA; Ercelep O; Dane F; Yumuk PF
Indian J Cancer; 2023; 60(2):179-184. PubMed ID: 36861712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]